Novartis Bets on India R&D Hub Post-Divestment
THE SEAMLESS LINK This strategic pivot sees Novartis AG doubling down on India’s evolving research ecosystem. Shedding its…
Roche to acquire Pathai for up to $1.05B
Roche Holding AG has agreed to acquire Pathai Inc. for up to $1.05 billion in a bid to…
Swiss startup Moonlight AI raises €2.8 million to turn routine blood and cytology imaging into genomic insights
Moonlight AI, a Swiss startup building image analysis software for clinical-grade diagnostics, has closed a €2.8 million ($3.3…
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern…
Managing Quality of Life with CML
Understanding chronic myeloid leukemia Chronic myeloid leukaemia (CML) is a type of cancer that develops in the blood-forming…
C4 Therapeutics, Roche pact brings $20M upfront
C4 Therapeutics (Nasdaq: CCCC) expanded its long-term partnership with Roche on April 9,…
The Power of PRECISION: Using AI to Navigate the Future of Prostate Cancer Care
Precision medicine treatment options in metastatic prostate cancer are expanding rapidly—and while it allows care to be tailored…
Roche’s Oncology Pipeline Shows Promise in Treating Aggressive Brain Metastases
Roche’s trastuzumab, capecitabine, and tucatinib combo more than doubled median survival to 10 months in HER2+ breast cancer…
Novartis Bolsters Oncology Pipeline with Multi-Billion Dollar Acquisition
Novartis bets up to $3B on Pikavation’s SNV4818, a drug candidate aimed at reducing side effects in breast…
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
Novartis acquires Synnovation’s breast cancer drug for up to $3 billion
Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a…
25 Year Anniversary of Innovation in Treating CML
Twenty-Five Years of Community: How Living With CML Has Changed—and Brought Patients Together Discussion notes from the Second…